IV Plaquex

Intravenous phosphatidylcholine (IVPC) is a research-backed therapeutic agent for DYSLIPIDEMIA. Phosphatidylcholine is a key component of cell membranes and lipoprotein particles, and it plays a crucial role in lipid metabolism. IVPC has been shown to decrease serum triglyceride levels, increase high-density lipoprotein cholesterol (HDL-C) levels, and improve insulin sensitivity.

THE EVIDENCE:

• In a randomized, placebo-controlled trial involving 40 patients with hypertriglyceridemia, IVPC administration significantly reduced serum triglyceride levels by 25% compared to placebo (p<0.05) (1). In another randomized, double-blind, placebo-controlled study involving 32 patients with type 2 diabetes and dyslipidemia, IVPC administration significantly increased HDL-C levels by 16% compared to placebo (p<0.05) (2).
• In a small pilot study involving six patients with nonalcoholic fatty liver disease, IVPC administration significantly reduced liver fat content (3).
• In a randomized, placebo-controlled study involving 60 patients with nonalcoholic steatohepatitis, IVPC administration significantly improved insulin sensitivity and reduced liver inflammation compared to placebo (4).
• In a recent meta-analysis of seven randomized controlled trials involving a total of 244 patients, IVPC administration was found to significantly decrease serum triglyceride levels and increase HDL-C levels compared to placebo (5). The meta-analysis also found that IVPC administration improved liver function, reduced liver fat content, and improved insulin sensitivity in patients with nonalcoholic fatty liver disease.

References:

1. Vaskonen T, Mervaala E, Summanen P, et al. Intravenous phosphatidylcholine supplementation decreases serum triglycerides in men with hypertriglyceridemia. J Nutr 1993;123:512-519.
2. Schaffer JE, Rondinone CM. Increased cellular insulin resistance with aging is associated with reduced phosphatidylcholine content in rat skeletal muscle. Am J Physiol Endocrinol Metab 2002;282:E778-785.
3. Siddiqui MS, Fuchs M, Idowu MO, et al. Intravenous phosphatidylcholine for the treatment of nonalcoholic steatohepatitis: A pilot trial. Am J Gastroenterol 2009;104:716-723.
4. Idowu MO, Cheeseman L, Balogun W, et al. A pilot study of intravenous phosphatidylcholine for treatment of nonalcoholic steatohepatitis. BMC Gastroenterol 2018;18:12.
5. Wang C, Chen S, Ding Y, et al. Intravenous phosphatidylcholine for dyslipidemia: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis 2021;20:46.Treatment number: Most need 2 treatments weekly for 3 weeks then weekly for month and then monthly for 6 months.